Merck MRK announced that the FDA has accepted ... clesrovimab (MK-1654), designed to protect infants from respiratory syncytial virus (RSV) disease entering their first RSV season.

Co., Inc. (NYSE:MRK), a global healthcare leader, faces a complex landscape of opportunities and challenges as it navigates the competitive biopharmaceutical industry. This comprehensive analysis ...